← Back to Clinical Trials
Recruiting NCT06074549

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System

Trial Parameters

Condition Coronary Artery Disease
Sponsor Elixir Medical Corporation
Study Type OBSERVATIONAL
Phase N/A
Enrollment 5,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-10
Completion 2028-12
Interventions
DynamX Novolimus-eluting Coronary Bioadaptor System

Brief Summary

The goal of this registry is to confirm the safety, and performance of the DynamX Coronary Bioadaptor System in patients with coronary artery disease.

Eligibility Criteria

Inclusion Criteria: 1. Over 18 years of age 2. Patient understands the trial requirements and treatment procedures and provides informed consent 3. Patient indicated for PCI with stent implantation and receive at least one DynamX Bioadaptor implant in accordance with the product's Instructions for Use (IFU). Exclusion Criteria: 1. Target Lesion(s) in the left main artery 2. Prior venous or arterial bypass grafts 3. In-stent restenosis 4. Patient is currently participating in another clinical trial with an investigational device or an investigational drug that has the potential to impact study results (e.g., anti-thrombotic or anti-platelet medications) that has not yet completed its primary endpoint 5. Patient is, in the opinion of the Investigator, unable to comply with the requirements of the study protocol or is unsuitable for the registry for any reason

Related Trials